Article
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Cancer immunology research - 1 Nov 2020
Jaiswal Ashvin R, Liu Arthur J, Pudakalakatti Shivanand, Dutta Prasanta, Jayaprakash Priyamvada, Bartkowiak Todd, Ager Casey R, Wang Zhi-Qiang, Reuben Alexandre, Cooper Zachary A, Ivan Cristina, Ju Zhenlin, Nwajei Felix, Wang Jing, Davies Michael A, Davis R Eric, Wargo Jennifer A, Bhattacharya Pratip K, Hong David S, Curran Michael A
Abstract excerpt
Despite the clinical success of T-cell checkpoint blockade, most patients with cancer still fail to have durable responses to immunotherapy. The molecular mechanisms driving checkpoint blockade resistance, whether preexisting or evolved, remain unclear. To address this critical knowledge gap, we treated B16 melanoma with the combination of CTLA-4, PD-1, and PD-L1 blockade and a Flt3 ligand vaccine (≥75%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.